Purpose This is a phase-I study of gefitinib in combination with temozolomide in patients
with gliomas. The goal of the study was to define the maximum tolerated dose (MTD) and to …

Introduction Epidermal growth factor receptors EGFR and ErbB2 are overexpressed in
schwannomas and meningiomas. Preclinical and clinical data indicate that lapatinib, an …

Summary Background A prospective Phase II study of irinotecan (CPT-11) in adult patients
with recurrent surgery and radiotherapy-refractory WHO Grade I meningioma. Methods …

OBJECTIVE Patients with atypical and malignant (WHO Grade II and III) meningiomas have
a worse prognosis than patients with benign (WHO Grade I) meningiomas. However, there is …

PURPOSE: To determine the safety and efficacy of gefitinib, an epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitor, in combination with radiation for newly diagnosed …

Purpose Meningiomas are the most frequently diagnosed intracranial neoplasms. Usually,
they are treated by surgical resection in curative intent. Radiotherapy and stereotactic …

BACKGROUND Recurrence rates for atypical and anaplastic meningiomas range between
9% and 50% after gross total resection and between 36% and 83% after subtotal resection …

OBJECTIVE: Recurrent atypical and malignant meningiomas are difficult to treat
successfully. Chemotherapy to date has been unsuccessful, and radiosurgery is limited to …

Objective Intracranial atypical meningiomas have a greater rate of recurrence than benign
meningiomas. Scant literature, however, is available regarding the treatment and prognosis …

Recurrence rates of meningiomas have been widely reported in the literature, but it remains
challenging for clinicians to predict recurrence rate depending on treatment, patient …